Safety and Tolerability of a Novel Malathion Formulation in Infants and Toddlers With Head Lice
Status:
Terminated
Trial end date:
2006-12-01
Target enrollment:
Participant gender:
Summary
In a previous phase II study, the safety and efficacy of a novel formulation of malathion
0.5% was evaluated in patients 2 years of age and older. Based on the results of that study,
this formulation is currently in a phase III study for that population.
The current study will use blood markers and clinical evaluations to determine the safety and
tolerability of this formulation when used in children 6-24 months of age.